Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.56 |
| ▸ | CTSS | P25774 | 5/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 6/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3726757 | 0.89 | CTSK (0.58) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL3726766 | 0.89 | CTSK (0.58) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL31551112 | 0.89 | CTSK (0.58) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL18762606 | 0.87 | CTSK (0.56) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL31407449 | 0.87 | CTSK (0.56) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL3768454 | 0.86 | CTSK (0.55) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL27444793 | 0.85 | CTSK (0.54) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL19245139 | 0.85 | CTSK (0.53) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL8277352 | 0.85 | CTSK (0.53) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL18762617 | 0.85 | CTSK (0.53) | CTSKCTSSHDAC4HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040030155-A1 | Process for preparing active esters | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-02-12 | — | — | US | claimed |
| EP-1350790-A1 | PROCESS FOR PREPARING ACTIVE ESTERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-10-08 | — | — | EP | claimed |
| US-7427634-B2 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-09-23 | — | — | US | disclosed |
| US-7351721-B2 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| EP-0997147-B1 | AMINO ACID DERIVATIVES | ONO PHARMACEUTICAL CO (JP) | 2006-03-15 | — | — | EP | disclosed |
| US-6903119-B1 | Amino acid derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-07 | — | — | US | disclosed |
| US-20050009890-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. | 2005-01-13 | — | — | US | disclosed |
| US-20040030155-A1 | Process for preparing active esters | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-02-12 | — | — | US | disclosed |
| US-20030232806-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. | 2003-12-18 | — | — | US | disclosed |
| EP-1350790-A1 | PROCESS FOR PREPARING ACTIVE ESTERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-10-08 | — | — | EP | disclosed |
| US-6605608-B1 | Such as n-(1-benzylpiperidin-4-yl)-3-cyclohexylmethylthio-2-((4R)-3-t -butoxycarbonylthiazolidin-4-ylcarbonylamino)propan-a mide; n-type calcium channel inhibitors | ONO PHARMACEUTICAL CO., LTD (JP) | 2003-08-12 | — | — | US | disclosed |
| EP-1097929-A1 | AMINO ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-05-09 | — | — | EP | disclosed |
| EP-1090912-A1 | AMINO ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009890-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | CACNA1I, CACNA1B, CACNA1A | CTSK 895/4885CTSS 601/4885HDAC4 4340/4885 |
| US-20040030155-A1 | Process for preparing active esters | CES1, CYP3A4, CYP3A5 | CTSK 1139/4885CTSS 711/4885HDAC4 578/4885 |
| US-20030232806-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | CACNA1I, CACNA1S, CACNA1B | CTSK 1082/4885CTSS 642/4885HDAC4 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.